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Overactive bladder (OAB) is defined as urgency, with or without urge incontinence,
usually accompanied by increased daytime frequency and nocturia.1 OAB is a
serious health problem because of its high prevalence and its significantly asso-
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Purpose: In order to gain insight into the physicians’ awareness of and attitude
towards management of overactive bladder (OAB) in males, we performed a
nationwide survey of the current strategies that urologists use to diagnose and
manage OAB in male patients. Materials and Methods: A probability sample
was taken from the Korean Urological Association Registry of Physicians, and a
random sample of 289 Korean urologists were mailed a structured questionnaire that
explored how they manage benign prostatic hyperplasia (BPH). Results: A total of
185 completed questionnaires were returned. The consent rate in the survey was
64.5%. Eighty-one (44%) urologists believed that of all males with lower urinary
tract symptoms (LUTS), 20% or more had OAB and 72 (39%) believed that 10-
20% had OAB. Half of the urologists surveyed believed that the most bothersome
symptom in male OAB patients was nocturia. Seventy-three percent of respondents
reported that they prescribed alpha blockers with anticholinergics for first line
management, while 19% of urologists prescribed alpha blocker monotherapy but
not anticholinergics for OAB patients. Though acute urinary retention (AUR) was
considered the anticholinergic adverse event of most concern, the most frequently
observed adverse event was dry mouth (95%). Conclusion: The present study
provides insights into urologist views of male OAB. There is a discrepancy
between the awareness of urologists and actual patterns of diagnosis and treatment
of male OAB. This finding indicates the need to develop further practical
guidelines based on solid clinical data.
Key Words: Overactive bladder, physician’s practice patterns, bladder outlet
obstruction, benign prostatic hyperplasia, anticholinergics
Received: July 8, 2009
Revised: August 9, 2009
Accepted: August 21, 2009
Corresponding author: Dr. Byung Ha Chung,
Department of Urology, Yonsei University
College of Medicine, 712 Eonju-ro, 
Gangnam-gu, Seoul 135-720, Korea.
Tel: 82-2-2019-3474, Fax: 82-2-3462-8887
E-mail: chung646@yuhs.ac 
∙The authors have no financial conflicts of
interest.
© Copyright:
Yonsei University College of Medicine 2010
This is an Open Access article distributed under the
terms of the Creative Commons Attribution Non-
Commercial License (http://creativecommons.org/
licenses/by-nc/3.0) which permits unrestricted non-
commercial use, distribution, and reproduction in any
medium, provided the original work is properly cited.
INTRODUCTION
ciated burden. The EPIC study2 reported that the overall
prevalence of OAB is 12%, with similar rates in men and
women, and that the prevalence of OAB increases with age. 
The treatment of lower urinary tract symptoms (LUTS)
in men is complicated by the fact that storage and voiding
symptoms frequently coexist.3 It is unclear whether storage
symptoms may develop secondary to bladder outlet obstruc-
tion (BOO) in men.4 However, storage symptoms often
occur independently of BOO and persist in many men des-
pite pharmacologic or surgical treatment.5  Therefore, thera-
pies that target the prostate often fail to alleviate OAB sym-
ptoms and may not be the most appropriate therapy for
men with storage LUTS.3
At present, relatively little is known about clinical pres-
cribing patterns of OAB in Asia, although several studies
in other countries have revealed underdiagnosis of OAB.6,7
To gain insight into urologist awareness and attitudes toward
management of OAB in males, we performed a nationwide
survey in Korea of the current strategies urologists use for
diagnosis and management of patients with OAB.
We obtained a probability sample (n = 448) of Korean
urologists from the Korean Urological Association (KUA)
Registry of Physicians and selected 289 participants who
were informed of the purpose of the survey and agreed to
be enrolled before the survey began. The eligibility criteria
required that participants be urologists not in residency
training and in active practice at least 20 hours per week. 
The survey was conducted from October 2008 to
November 2008. It was based on a structured question-
naire delivered via e-mail. Participants received the survey
instrument, which consisted of a cover letter that identified
the author and described the purpose of the survey and the
survey questionnaire itself. The questionnaire was devel-
oped by the authors of this paper. The survey instrument
was also reviewed and revised by additional experts and
pretested for clarity and convenience. The survey question-
naire was divided into three parts. Part One of the ques-
tionnaire focused on the patient pool and structure, and
was comprised of four separate items. Part Two of the
questionnaire comprised seven separate items related to the
perception and diagnosis pattern of patients with OAB.
Part Three of the questionnaire comprised 10 separate items
related to the strategy used for medication and the indivi-
dual physician’s preference concerning medical therapy
(see Appendix). The data collected from the survey are
presented descriptively; therefore, no statistical analyses
were performed.
A total of 185 completed questionnaires were returned by
urologists. The consent rate in the survey was 64.5%
(73.2% in private clinics, 62.7% in general hospitals), and
the compliance rate for the 289 urologists who initially
agreed to participate was 64.0%. In the total sample, 26%
of urologists described their practice as ‘private clinics’,
while 74% described their practice as ‘hospital practice’. 
Urologist perceptions and diagnosis of OAB 
In the questionnaire, the case studies of two 60 year-old
patients, one male and one female, with urinary urgency,
frequency, and nocturia were presented. Neither of these
patients had physical or laboratory abnormalities. One
hundred thirteen urologists (61%) agreed with an OAB
diagnosis; however, 66 urologists (36%) partially agreed
and 6 (3%) disagreed. 
In response to a question asking what information the
urologist felt that he/she need to diagnose OAB in males,
97 (52%) urologists replied that they required information
obtained from interviews, questionnaires, and objective
tests (Table 1). The International Prostate Symptom Score
(IPSS) questionnaire was the most commonly-used ques-
tionnaire, while a voiding diary was the second most com-
mon diagnostic method. OAB questionnaires (OABQ)
were used by about 15% of respondents. 
Urologists thought that the most bothersome symptom
of OAB was nocturia (n = 100, 54%), and the second most
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MATERIALS AND METHODS
Table 1. The Incidence of Diagnostic Tests for Patients with
OAB as the Initial Evaluation (%)
Initial evaluation (%) 
History taking only 30 (16)
History + Questionnaire 37 (20)
History + Questionnaire + 
97 (52)
Objective tests
History + Objective tests 21 (11)
Others 0
OAB, overactive bladder.
Fig. 1. Urologist perceptions of the most bothersome symptoms of male OAB.
OAB, overactive bladder.
RESULTS
bothersome symptom was urgency (n = 54, 29%) (Fig. 1).
However, only 83 (45%) urologists believed that the ini-
tiating factors of OAB in males could be determined in
patients with symptoms of OAB. 
Management of patients with OAB 
Ninety-nine percent of respondents (n = 182) replied that
they chose medical treatment as the initial management
option for patients with OAB. Table 2 shows the initial treat-
ment patterns for patients with OAB. Seventy-three percent
of the respondents reported that they prescribed alpha
blockers with anticholinergics as first line management,
while anticholinergic monotherapy or alpha blocker mono-
therapy was used less frequently (6% vs. 16%, respectively).
Fifty-six percent of the respondents prescribed alpha bloc-
kers for a minimum of two to four weeks before anticholin-
ergics. In response to the question concerning which mana-
gement option to use for patients unresponsive to initial
management, 68 respondents (36%) replied that they
would switch to another medication while 61 respondents
(33%) replied that they would continue prescribing the
current medication with behavioral therapy. Another 55
respondents (30%) replied that they would increase the
dosage (Fig. 2). When urologists prescribed anticholin-
ergics, their primary concern was acute urinary retention
(AUR), and the second was dry mouth (59% vs. 11%, res-
pectively). However, the most frequently experienced
adverse event was dry mouth (95%), while AUR was un-
common (3%). With regard to which management option
the urologists would choose if adverse events occurred,
37% replied that they would change to another anticholin-
ergic, 29% replied that they would reduce the dosage, 21%
replied that they would continue administering the same
drug, and 11% reported that they would discontinue
prescribing the drug. 
We surveyed the views of a broad range of urologists based
in both hospitals and private clinics. The response rate of
64.0% in this study is much higher than the 5-10% response
rates achieved through postal surveys.8
International differences in OAB prevalence have been
observed. A multinational study in six European countries
demonstrated significant variation in prevalence, with Spain
reporting the highest (22%) prevalence and France report-
ing the lowest (12%) prevalence.7 However, in Asian sam-
prles, the prevalence of OAB has been reported to be even
higher. The prevalence of OAB in Asian men was recently
evaluated in 11 Asian countries. A questionnaire was sent
to over 2,000 men aged from 18 to 70 years.9 An OAB
prevalence of about 30% was observed in the Asian male
population (range, 14-84%). Frequency and urgency were
the most commonly reported symptoms, while 13% of
individuals examined reported urge incontinence. How-
ever, it is still unclear whether the higher prevalence rate in
Asia is truly reflective of international differences. More-
over, there are fewer reports about the incidence of male
OAB than all male LUTS. It has been observed that 45%
to 75% of men with BOO have OAB symptoms.10,11 How-
ever, in our survey, 56% of urologists believed that the
incidence of OAB patients among all male LUTS was less
than 20%. This finding may result from a discrepancy
between the awareness of the physician and his/her pati-
ents. Most urologists focus on LUTS/benign prostatic
hyperplasia (BPH), especially in elderly men, and do not
regard OAB symptoms to be a serious problem until they
become severe. Further studies that focus on the real
incidence of OAB patients among all male LUTS patients
are required to compare the findings for Asian populations
with those for Western populations. 
In our survey, 54% of respondents regarded nocturia as
the most bothersome symptom of male OAB. This result,
however, has not been consistently observed across epide-
miologic studies. Johansson, et al.12 suggested that nocturia
is one of the most bothersome symptoms of LUTS in men
and women. Another study noted that nocturia was the
second most bothersome symptom after urinary urgency.13
Although nocturia is highly prevalent in elderly people, it
only has a minor impact on daily life and few individuals
seek medical care.14 This is largely because Koreans believe
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Fig. 2. Treatment alternatives for male OAB patients who do not respond to
medication.  OAB, overactive bladder.
Table 2. The Incidence of Initial Treatment Patterns for 
Patients with OAB (%)
Initial treatment (%)
Alpha blocker only 33 (18)
Alpha blocker + 5ARI 0 (0)
Alpha blocker + Anti cholinergic 135 (73)
Alpha blocker + 5ARI + 
10 (5)
Anti cholinergic
Anti cholinergic only 5 (3)
Others 2 (1)
5ARI, 5 alpha reductase inhibitors; OAB, overactive bladder.
that nocturia is a normal consequence of aging and not a
disease. This, however, may indicate that  patients who
complain of nocturia in Korea may have more serious noc-
turia than patients surveyed in other studies. 
There is a rationale for prescribing anticholinergics not
only to men with LUTS, but also to men with OAB. How-
ever, guidelines from the European Association of Urolo-
gists make no mention of the possible therapeutic role of
anticholinergics for treating storage symptoms in such
patients. Moreover, many physicians are still reluctant to
prescribe anticholinergics due to the concern of urinary
retention, especially in men with BOO. Several studies
have reported that prescribing anticholinergics to men with
LUTS or even BOO does not seem to elevate the risk of
AUR.15,16 In our study, almost all urologists agreed that
anticholinergics are needed to treat male OAB. However,
19% of urologists did not prescribe anticholinergics and
instead opted for alpha blocker monotherapy in OAB
patients. The most frequently experienced adverse event
was dry mouth, but urologists were most concerned about
AUR. 
These findings are interesting for several reasons. Urolo-
gists in Korea appear to give more weight to BOO in elderly
men than OAB, and are concerned with prescribing anti-
cholinergics to males with OAB. It is obvious that there is
significant overlap between the male OAB population and
men with LUTS. Both may result from pathophysiologic
mechanisms such as benign prostatic enlargement, benign
prostatic obstruction, detrusor overactivity, or from a com-
bination of prostate and bladder dysfunctions.17 It is deba-
table whether a distinction between male LUTS and OAB
is clinically relevant and whether or not it influences treat-
ment decisions. Further epidemiologic studies are needed
to confirm the effect of actual practice patterns in males
with OAB.
The results of the current survey should be viewed within
the context of its limitations. This survey is not an epide-
miologic study. The data used in this survey are based only
on the awareness of urologists, which could introduce a
degree of subjectivity. Second, all data were collected by
an e-mail survey and self-administered questionnaires.
Different survey modes may have different sampling
errors, response rates, data completeness, and measurement
errors.18 In particular, fewer urologists in private clinics
than urologists working in hospitals participated in this
study. This could introduce a sampling error given that the
general distribution of Korean urologists in private clinics
is about half that of all the urologists. However, despite
these limitations, this descriptive survey indicates the need
for more practical diagnosis guidelines and a treatment
consensus. 
In conclusion, in this study, we have provided insights
into urologist views of male OAB. There is a discrepancy
between urologist awareness and the actual diagnosis and
treatment of male OAB. This finding indicates the need to
further develop practical guidelines based on solid clinical
data, and to ensure that these guidelines are widely pro-
moted and accepted by the urological community.
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APPENDIX
Questionnaire used to assess how Korean urologists view male overactive bladder
Part 1. Patient pool and structure
1. How many outpatients do you see in a week?
1) 100 or less   2) 100-150   3) 150-200   4) 200-250   5) 250-300   6) 300 or more
2. What is the proportion of male OAB patients to all patients who have LUTS?
1) > 20%   2) 10-20%   3) 5-10%   4) 0-5%
3. How many patients with overactive bladder who need treatment with pharmacological agents do you see in a month? 
Approximately ————— % of all male patients 
4. During the past decade, do you think the prevalence of patients with BPH in Korea has 
1) Increased considerably   2) Increased   3) Not changed   4) Decreased   5) Decreased considerably
Part 2. Perception and diagnosis pattern of OAB 
1. A 60-year-old man had the chief complaint of urinary urgency, frequency, and nocturia (3-4 voids per night). No
physical or laboratory abnormalities were noted. Another 60-year-old woman had the same chief complaint as
above. Do you agree with an OAB diagnosis in these two patients?
1) Absolutely agree   2) Partially agree   3) Disagree
2. Overactive bladder (OAB) is defined as urgency, with or without urge incontinence, usually accompanied by
increased daytime frequency and nocturia according to the International Continence Society (ICS). Do you agree
with this definition? 
1) Absolutely agree   2) Partially agree   3) Partially disagree   4) Disagree
3. Which of the following do you think are the initial diagnostic tests for OAB? (choose one)
1) History taking only   2) History taking + Questionnaire   3) History taking + Questionnaire + Objective test 
4) History taking + Objective test   5) Questionnaire + Objective test   6) Others
5. Which of the following symptoms do you feel that male OAB patients find the most bothersome? (you can choose
more than one)
1) Urgency   2) Incontinence   3) Frequency   4) Nocturia   5) Weak stream   6) Others 
6. Do you routinely use a voiding diary for the differential diagnosis of OAB and nocturnal polyuria?
1) Routinely use   2) Sometimes use   3) Seldom use   4) Never 
7. Which of the following questionnaires do you routinely use for male OAB patients? 
1) IPSS   2) Voiding diary   3) PPBC (Patient Perception of Bladder Condition) 
4) KHQ (King’s Health Questionnaire)   5) OABSS (OAB Symptom Score)   6) OABQ   7) ICIQ Male LUTS 
8) Patient’s Most bothersome LUTS      9) PPTB (Perception of Treatment Benefit: BSW)
10) PPIUS (Patient Perception of Intensity of Urgency Scale)   11) IUSS (Indevus Urgency Severity Scale) 
12) UPS (Urgency Perception Score: Patient Perception of Urgency)   13) Others
Part 3. Management of patients with OAB
1. Medical treatment in male OAB patients is needed as the first line therapy. Do you agree?
1) Absolutely agree   2) More than half agree   3) Less than half agree   4) Disagree
2. What is the most common drug you prescribe for first line therapy in male OAB patients?
1) Alpha blockers only   2) Alpha blockers + 5 ARIs   3) Alpha blockers + Anticholinergics
4) Alpha blockers + 5ARIs + Anticholinergics   5) Anticholinergics only   6) Others. 
3.  Which is recommended as the optimal minimum duration of alpha blocker medication assuming that the treatment
in a male OAB patient is initiated with an alpha blocker and then followed with an anticholinergic agent. 
1) 1-2 weeks   2) 2-4 weeks   3) 4-8 weeks   4) 8-12 weeks   5) 12 weeks or more
4.  Which of the next steps do you prefer to follow in male OAB patients who do not respond to medical treatment?
1) Increase the dosage of the same drug   2) Recommend behavioral therapy and continue use of the same drug
3) Switch to another drug   4) Consider surgery 
5. Which of the following do you find of greatest concern when you prescribe anticholinergics?
1) AUR   2) Dry mouth   3) Constipation   4) Blurred vision   5) GI trouble   6) Voiding difficulty   7) Others
6. Which of the following adverse events have you experienced most frequently following the prescription of
anticholinergics?
1) AUR   2) Dry mouth   3) Constipation   4) Blurred vision   5) GI trouble   6) Voiding difficulty   7) Other
7. How do you manage adverse events resulting from anticholinergic medication?
1) Continue the same drugs   2) Decrease the drug dosage   3) Switch to other anticholinergics 
4) Discontinue use of anticholinergics   5) Other
8. Have you experienced AUR following prescription of anticholinergic medication?
1) Yes (more than half)   2) Yes (less than half)   3) No
9. What do you recommend for prevention of AUR following prescription of anticholinergic medication?
1) Medicating only select patients   2) Decreasing the dosage 
3) Administering anticholinergic medication only after alpha blockers have been used   4) Taking no action   5) Other 
10. Which of the following criteria do you consider most important for selecting male OAB patients who will not
experience AUR following anticholinergic medication?
1) Residual volume   2) Irritative symptoms   3) Storage symptoms   4) Prostate volume   5) Other
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